AU2001263215A1 - Method for treating cartilage disorders - Google Patents

Method for treating cartilage disorders

Info

Publication number
AU2001263215A1
AU2001263215A1 AU2001263215A AU6321501A AU2001263215A1 AU 2001263215 A1 AU2001263215 A1 AU 2001263215A1 AU 2001263215 A AU2001263215 A AU 2001263215A AU 6321501 A AU6321501 A AU 6321501A AU 2001263215 A1 AU2001263215 A1 AU 2001263215A1
Authority
AU
Australia
Prior art keywords
igf
cartilage
cartilage disorders
treating cartilage
igfbp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001263215A
Other languages
English (en)
Inventor
Yves Dubaquie
Ellen H. Filvaroff
Henry B. Lowman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2001263215A1 publication Critical patent/AU2001263215A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001263215A 2000-05-16 2001-05-16 Method for treating cartilage disorders Abandoned AU2001263215A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20449000P 2000-05-16 2000-05-16
US60204490 2000-05-16
US24898500P 2000-11-15 2000-11-15
US60248985 2000-11-15
PCT/US2001/015904 WO2001087323A2 (en) 2000-05-16 2001-05-16 Method for treating cartilage disorders

Publications (1)

Publication Number Publication Date
AU2001263215A1 true AU2001263215A1 (en) 2001-11-26

Family

ID=26899527

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001263215A Abandoned AU2001263215A1 (en) 2000-05-16 2001-05-16 Method for treating cartilage disorders

Country Status (9)

Country Link
US (4) US20030069177A1 (da)
EP (1) EP1282437B1 (da)
AT (1) ATE389416T1 (da)
AU (1) AU2001263215A1 (da)
DE (1) DE60133271T2 (da)
DK (1) DK1282437T3 (da)
ES (1) ES2301547T3 (da)
HK (1) HK1050321A1 (da)
WO (1) WO2001087323A2 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1099443A1 (en) 1999-11-11 2001-05-16 Sulzer Orthopedics Ltd. Transplant/implant device and method for its production
US7387889B2 (en) * 2002-08-22 2008-06-17 Massachusetts Institute Of Technology Measurement of concentrations and binding energetics
ES2405080T3 (es) * 2003-02-26 2013-05-30 Zimmer Orthobiologics, Inc. Preparado para la reparación de un tejido cartilaginoso, en particular de defectos de cartílagos articulares
CA2558497A1 (en) * 2004-03-05 2005-09-15 Synthes (U.S.A.) Use of a mixture for the production of an agent for treating defective or degenerated cartilage in the production of natural cartilage replacement in vitro
US20080031819A1 (en) * 2004-06-09 2008-02-07 Beth Israel Deaconess Medical Center Compositions and Methods that Enhance Articular Cartilage Repair
EP1764117A1 (en) 2005-09-20 2007-03-21 Zimmer GmbH Implant for the repair of a cartilage defect and method for manufacturing the implant
US7850983B2 (en) 2006-02-07 2010-12-14 Spinalcyte, Llc Methods and compositions for repair of cartilage using an in vivo bioreactor
CL2007002502A1 (es) * 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
US20100137204A1 (en) * 2006-12-29 2010-06-03 Zheng Xin Dong Glp-1 pharmaceutical compositions
EP3470093B1 (en) 2008-10-06 2020-08-19 3-D Matrix Ltd. Tissue plug
BRPI0922344A2 (pt) 2008-12-19 2017-10-24 3B Pharmaceuticals Gmbh inibidores de tfpi e métodos de uso
ES2983470T3 (es) 2010-03-19 2024-10-23 Takeda Pharmaceuticals Co Inhibidores del TFPI y métodos de uso
EP3760707A1 (en) * 2011-11-09 2021-01-06 Spinalcyte, LLC Dermal fibroblasts for treatment of degenerative disc disease
JP2015514070A (ja) 2012-03-21 2015-05-18 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ Ｔｆｐｉ阻害剤および使用方法
WO2014004467A1 (en) * 2012-06-25 2014-01-03 The Brigham And Women's Hospital, Inc. Selective cartilage therapy
WO2014008400A2 (en) 2012-07-06 2014-01-09 3-D Matrix, Inc. Fill-finish process for peptide solutions
CN105452447A (zh) 2013-06-19 2016-03-30 脊核细胞有限责任公司 用于软骨细胞应用的脂肪细胞
WO2015136370A2 (en) 2014-03-10 2015-09-17 3-D Matrix, Ltd. Sterilization and filtration of peptide compositions
EP3116524B1 (en) 2014-03-10 2018-11-28 3-D Matrix Ltd. Autoassembling peptides for the treatment of pulmonary bulla
JP6628733B2 (ja) 2014-03-10 2020-01-15 株式会社スリー・ディー・マトリックス 自己組織化ペプチド組成物
WO2017120092A1 (en) 2016-01-06 2017-07-13 3-D Matrix, Ltd. Combination compositions
CN117085140A (zh) 2017-12-15 2023-11-21 立美基股份有限公司 表面活性剂肽纳米结构及在药物递送中的用途

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) * 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US3721252A (en) * 1971-04-01 1973-03-20 Catheter And Instr Corp Spring guide washer
US4444047A (en) * 1979-06-29 1984-04-24 Vdo Adolf Schindling A.G. Apparatus for determining the fuel consumption of injection internal combustion engines
NO154236C (no) 1979-07-16 1986-08-20 Ciba Geigy Ag Etterbehandling av med flammebeskyttelsesmiddel behandlede, celluloseholdige fibermaterialer med flytende ammoniakk.
US4511503A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
WO1985000831A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
AU598205B2 (en) * 1985-08-22 1990-06-21 Gropep Pty Ltd Peptide analogues of mammalian insulin-like growth factor-1
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
SE8505922D0 (sv) 1985-12-13 1985-12-13 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
ES2058341T3 (es) 1987-04-06 1994-11-01 Celtrix Pharma Subunidades de proteina portadoras de somatomedina humana y proceso para producirlas.
ES2007309T3 (es) 1987-04-23 1994-11-01 Monsanto Co Secrecion del factor de crecimiento insulinoide 1 en e.coli.
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4876242A (en) * 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
EP0346429B1 (en) * 1987-12-24 1994-12-28 Gropep Pty. Ltd. Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2)
US5470828A (en) * 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
ATE86496T1 (de) * 1988-02-05 1993-03-15 Ciba Geigy Ag Verwendung von igf i zur herstellung eines praeparates fuer die behandlung von nierenkrankheiten.
DK131988A (da) 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
WO1989009792A1 (en) 1988-04-12 1989-10-19 Synergen, Inc. Method for potentiating and inhibiting insulin-like growth factor activity
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US6780613B1 (en) * 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
CA2007886A1 (en) 1989-01-17 1990-07-17 Marvin L. Bayne Human insulin-like growth factor analogs with reduced binding to 28 k igf binding proteins and their production in yeast
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
GB8920381D0 (en) 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
SE500903C2 (sv) 1989-12-20 1994-09-26 Atlas Copco Constr & Mining Bergborrningsrigg
ZA9010332B (en) 1989-12-22 1991-08-28 Ciba Geigy Method of reducing or preventing adverse effect of steroid therapy and compositions therefor
NZ236618A (en) 1990-01-03 1997-06-24 Ciba Geigy Ag Treating and preventing osteoporosis using insulin-like growth factor i (igf i) in conjunction with a bone antiresorptive active compound
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5364839A (en) 1990-06-18 1994-11-15 Genetics Institute, Inc. Osteoinductive pharmaceutical formulations
US5210017A (en) 1990-11-19 1993-05-11 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5593844A (en) 1990-11-19 1997-01-14 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
DE69129154T2 (de) * 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
SE9100099D0 (sv) 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
US5206023A (en) 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
ATE439435T1 (de) 1991-03-01 2009-08-15 Dyax Corp Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon
US5206235A (en) * 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
CA2114251C (en) * 1991-08-01 2007-11-06 Peter Gluckman Igf-1 to improve the neural condition
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
TW267102B (da) 1992-03-13 1996-01-01 Ciba Geigy
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
DK0659083T3 (da) 1992-06-12 2000-06-13 Einstein Coll Med Forebyggelse og behandling af perifer neuropati
GB9217696D0 (en) 1992-08-20 1992-09-30 Agricultural & Food Res Use of specific binding molecules
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
US5342763A (en) * 1992-11-23 1994-08-30 Genentech, Inc. Method for producing polypeptide via bacterial fermentation
EP0642350A4 (en) 1993-01-25 1995-06-28 Beth Israel Hospital PROCESS FOR MODIFICATION, DIAGNOSIS AND SCREENING OF IGF-I SENSITIVE CELL BARRIER CHARACTERISTICS.
JPH09500088A (ja) 1993-01-29 1997-01-07 アムジェン ボールダー インコーポレイテッド 創傷治癒用組成物
US5478852C1 (en) 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
SK281963B6 (sk) 1993-12-23 2001-09-11 Novo Nordisk A/S Zlúčeniny ovplyvňujúce uvoľňovanie rastového hormónu, farmaceutické prostriedky s ich obsahom a ich použitie
AU683121B2 (en) 1993-12-23 1997-10-30 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5597700A (en) * 1994-04-28 1997-01-28 California Research, Llc Method for detecting free insulin-like growth-factor-binding protein 1 and a test device for detecting the ruptures of fetal membranes using the above method
US5444047A (en) 1994-06-16 1995-08-22 Dipasquale; Gene Treatment of arthritic and post-surgical orthopedic conditions with Insulin-like Growth Factor-I
SE9402331D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab New use
SE9402370D0 (sv) 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
US5728676A (en) * 1994-09-08 1998-03-17 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
US5798337A (en) 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
US5596844A (en) * 1995-02-03 1997-01-28 Kalinowski; Juan R. Foldable portable building
SE9501472D0 (sv) 1995-04-21 1995-04-21 Pharmacia Ab Truncated IGF-I
US5622932A (en) * 1995-05-05 1997-04-22 Eli Lilly And Company IGF-1 superagonists
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
PT828758E (pt) 1995-05-26 2002-02-28 Theratechnologies Inc Analogos quimericos de corpo gordo-pro-grf com potencia biologica aumentada
AU6046696A (en) 1995-06-07 1996-12-30 Glaxo Group Limited Peptides and compounds that bind to a receptor
PT885242E (pt) 1995-06-07 2008-06-18 Glaxo Group Ltd Péptidos e compostos que se ligam a um receptor de trombopoietina
US5958872A (en) 1996-04-01 1999-09-28 Apoptosis Technology, Inc. Active survival domains of IGF-IR and methods of use
AU2676297A (en) 1996-04-17 1997-11-07 Neurocrine Biosciences, Inc. Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor
WO1998011913A1 (en) * 1996-09-16 1998-03-26 Dalhousie University Use of igf-i for the treatment of polycystic kidney disease and related indications
WO1998020036A1 (en) 1996-11-06 1998-05-14 Genentech, Inc. Constrained helical peptides and methods of making same
AU7891098A (en) 1996-12-27 1998-07-31 Daiichi Pharmaceutical Co., Ltd. Method for elevating the concentration of free insulin-like growth factor
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
CO4750643A1 (es) 1997-06-13 1999-03-31 Lilly Co Eli Formulacion estable de la insulina que contiene l-arginina y protamina
DE19757250A1 (de) 1997-12-22 1999-07-01 Forssmann Wolf Georg Prof Dr Insulin-like growth factor binding protein und seine Verwendung
AU3548999A (en) * 1998-04-03 1999-10-25 Chiron Corporation Use of igfi for treating articular cartilage disorders
AU767141B2 (en) 1998-10-02 2003-10-30 Celtrix Pharmaceuticals, Inc. Null IGF for the treatment of cancer
WO2000023469A2 (en) 1998-10-16 2000-04-27 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
AU762047B2 (en) * 1999-01-06 2003-06-19 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
JP2003518917A (ja) 1999-05-19 2003-06-17 ゼンコー 糖尿病の処置に有用なインシュリン様活性を有する新規タンパク質
CA2402780A1 (en) 2000-03-29 2001-10-04 Dgi Biotechnologies, L.L.C. Insulin and igf-1 receptor agonists and antagonists

Also Published As

Publication number Publication date
US20100130411A1 (en) 2010-05-27
DK1282437T3 (da) 2008-06-30
EP1282437B1 (en) 2008-03-19
US20030069177A1 (en) 2003-04-10
EP1282437A2 (en) 2003-02-12
WO2001087323A2 (en) 2001-11-22
DE60133271T2 (de) 2009-04-23
US8110548B2 (en) 2012-02-07
US7423017B2 (en) 2008-09-09
US7947650B2 (en) 2011-05-24
DE60133271D1 (de) 2008-04-30
US20030211992A1 (en) 2003-11-13
ES2301547T3 (es) 2008-07-01
HK1050321A1 (en) 2003-06-20
WO2001087323A3 (en) 2002-04-11
US20090011988A1 (en) 2009-01-08
ATE389416T1 (de) 2008-04-15

Similar Documents

Publication Publication Date Title
AU2001263215A1 (en) Method for treating cartilage disorders
WO2002072780A3 (en) Igf antagonist peptides
WO1998045427A3 (en) Insulin-like growth factor agonist peptides
CA2189657A1 (fr) Fractions polypeptidiques solubles de la proteine lag-3; procede de production; composition therapeutique; anticorps anti-idiotype
ATE343635T1 (de) Bmp-11 zusammenstellungen
ATE297202T1 (de) Verwendung von nichtimmununterdruckende verbindungen zur förderung von nervenregeneration
WO2000023469A3 (en) Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
EP2145897A3 (en) Therapeutic methods and compositions based on serrate proteins and nucleic acids
DE69713112D1 (de) Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin-analogen
IL115792A0 (en) Al-1 neurothophic factor
WO2004053059A3 (en) Mitoneet polypeptide from mitochondrial membranes, modulators thereof, and methods of using the same
AU3793493A (en) Therapeutic domains of von willebrand factor
AU1276399A (en) Neuronal uses of bmp-11
ATE408685T1 (de) Antimikrobielle peptide, abstammend von ubiquicidin
GB9509557D0 (en) PCNA binding substance
PT781341E (pt) Processo para a produção de proteínas recombinantes, plasmídeos e células modificadas
HUT64369A (en) Collagen binding protein and method for producing it
WO2001072826A3 (en) Oncogenic osteomalacia-related gene 1
EP0801133A3 (en) Hydroperoxide lyases
GB9416536D0 (en) Orphan receptor
EP0816498A3 (en) Excitatory amino acid receptor protein and related nucleic acid compounds
WO2001070808A3 (en) Angiogenesis - associated proteins, and nucleic acids encoding the same
DE60040668D1 (de) Antibakterielles protein chlamysin-b, dafür kodierendes gen und ein expresionssystem dafür
WO2001067097A3 (en) Method of identifying modulators of presenilin
EE200100234A (et) PRV-1-geen ja selle kasutamine